Mirati lung cancer candidate sitravatinib fails in phase 3; down 11%

• Mirati Therapeutics (NASDAQ:MRTX) said that a phase 3 trial of its non-squamous non-small cell lung cancer sitravatinib in combination with Bristol-Myers Squibb's Opdivo (nivolumab) did not meet its primary endpoint.
• The primary endpoint was overall survival with the combination compared to docetaxel.
• Shares are down 11% in after-hours trading.
• The trial was in patients who have failed on chemotherapy and immune checkpoint inhibitor therapy.
• Mirati (MRTX) said it would release the study data at later time.

More on Mirati and sitravatinib

• Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer

• Mirati Therapeutics: Suddenly A Battleground Stock